版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)
文檔簡介
-23-PatentRightsPurchaseAgreement專利購買合同核心提示:ThisPatentRightsPurchaseAgreement(thisAgreement)ismadeandenteredintoasof_________,_________,_________(M,D,Y).(theEffectiveDate)betweenAAA,Inc.(AAA),andDDD,Inc.(DDD).1.DEFINITIONS.1.1CationicLipidmeansthosecompoundsdThisPatentRightsPurchaseAgreement(thisAgreement)ismadeandenteredintoasof_________,_________,_________(M,D,Y).(theEffectiveDate)betweenAAA,Inc.(AAA),andDDD,Inc.(DDD).1.DEFINITIONS.1.1CationicLipidmeansthosecompoundsdescribedinUnitedStatesPatentNos._________and_________;UnitedStatesPatentApplicationSerialNo._________;andEuropeanPatentApplicationNo._________,totheextentsuchcompoundsarenotCodeblockerCompounds.1.2CodeblockerCompoundmeansanoligonucleotidethatbindsdirectlytoDNAorRNAwithinacellonaselectivebasisdeterminedbythenucleotidesequenceofthetargetDNAorRNAandexertsitsbiologicalactivitypredominantlythroughbindingtoDNAorRNAtoinhibitthetranscriptionorreplicationofthetargetDNAorRNAorbindingtoRNAtoinhibitthetranslation,processing,packagingorregulatoryactivityofthetargetRNA.ACodeblockerCompoundmayalsohaveamechanismofactionorbiologicalactivityotherthanoneconferredthroughdirectbindingtoRNAorDNAprovidedthat(i)thecompoundoriginallywasdesignedtobindatargetDNAorRNAand(ii)thefinalcompoundoranycompoundsusedtoderivethefinalcompoundwerenotidentifiedusingselectivepurificationandpolymeraseamplificationinanyfashion.Anoligonucleotide,isanyoligomerorpolymermadeup_________AnoligonucleotideincludesRNAorDNAfragments,andmaybecomposedofnaturallyoccurringornon-naturallyoccurringbases,sugarsorintersugarlinkages.Anoligonucleotidemayhavethebases,sugarsorintersugarlinkagespartiallyorcompletelyabsent.Oligonucleotidesmaybemadesuchthatadjacentnucleosideornucleosidefragmentsarelinkedtogetherbyphosphategroupsormodifiedornon-naturallyoccurringinternucleosidelinkagestoformtheinternucleosidebackboneoftheoligomer,whetherornotsuchlinkagesretainaphosphorousatominthelinkage.1.3OligonucleotideDeliverySystemmeansanycarrier,targetingentity,excipient,formulation,device,prodrug,covalentornoncovalentconjugate,encapsulatingvesicle,microcapsule,micro-ornanosphere,emulsion,ormicroemulsion,lipid,liposome,virosome,orartificialvialenvelopewhichwasdevelopedbyDDDonorpriortotheEffectiveDate,andwhich(i)enhancesthecellularpenetrationorcirculatinghalf-lifeofaCodeblockerCompound,(ii)selectivelydeliversaCodeblockercompoundtotheintendedtargettissue,cellorsubcellularcompartment,(iii)providessustainedreleaseofaCodeblockerCompoundfromadepotformulation,or(iv)otherwisefavorablyalterstheabsorption,distribution,metabolismorexcretionofaCodeblockerCompoundsoastoenhanceitspharmacologicalactivityofclinicalvalue.OligonucleotideDeliverySystemincludescationiclipids.1.4PatentRightsmeansthepatentsandpatentapplicationslistedinExhibitAattachedhereto.2.ASSIGNMENTSANDLICENSES.2.1DDDherebysellsandassignstoAAAallofDDD’sright,titleandinterestinPatentRights,subjecttotherightsofEEEInc.(EEE)undertheCollaborativeResearchAgreementbetweenEEEandDDDdated_________,_________,_________(M,D,Y)(theEEEAgreement),providedhowever,thattheassignmentofU.S.PatentNumber_________shallbesubjecttotheconditionprecedentthatDDDsettletheinterferenceinvolvingthispatentonconditionsofDDD’schoosing(includingconcedingpriority).DDDherebygrantsAAAanexclusive,royalty-free,worldwide,assignablelicense(withtherighttograntsublicenses)toU.S.PatentNumber_________beginningontheEffectiveDateandcontinuinguntilsuchtimethatDDDsettlestheinterferenceandtheassignmenttoAAAbecomeseffective.2.2DDDherebyassignsanddelegatestoAAA(andAAAacceptsandagreestoperform)allofDDD’srightsandobligationsundertheLicenseAgreementbetweenFFFCorporation(FFF)andDDDdated_________,_________,_________(M,D,Y)andamendedon_________,_________,_________(M,D,Y).AcopyofthewrittenconsenttosuchassignmentanddelegationsignedbyFFFisattachedheretoasExhibitB.IntheeventthatAAA,byreasonofthisAgreement,isrequiredtoindemnifyFFFunderSection8.1(b)oftheFFFLicenseAgreement,DDDwillindemnifyAAAuptoamaximumamountequaltoonehundredpercent(100%)oftotalroyaltiesreceivedbyDDDfromFFF;thereafter,DDDwillnothaveanyindemnityobligationstoAAArelatedtosuchAgreement.DDDwillcontinuetohonoritsobligationstoFFFforactivitiesprecedingtheEffectiveDateofthisAgreement.2.3SubjecttotherightsofFFFabove,AAAherebygrantstoDDDanexclusive,perpetual,irrevocable,royalty-free,worldwide,assignablelicense(withtherighttograntsublicenses)todirectlyorindirectlymake,havemade,use,import,exportorsellcompoundsandothersubjectmatterfallingwithinthescopeofPatentRightswhichare_________2.4DDDherebygrantstoAAAanonexclusive,perpetual,royalty-free,worldwide,assignablelicense(withtherighttograntsublicenses)tocompoundsandothersubjectmatterwhicharewithinthescopeofPatentRights,solelyforuseasintermediatesinthemanufactureofCodeblockerCompoundsoroligomers_________2.5AAAherebygrantstoDDDanon-exclusive,non-sublicensable,non-assignable,perpetual,irrevocable,royalty-free,worldwidelicenseunderPatentRightstomakeanduseCodeblockerCompoundsandOligonucleotideDeliverySystemsforinternalresearchpurposes,butnotforanycommercialpurpose.2.6AAAwillnothaveanyobligationstoDDDrelatingtoCodeblockerCompoundsorthisAgreementtotheextentarisingpriortotheEffectiveDate.2.7EachpartyherebyagreestoexecutesuchdocumentsandtotakesuchotheractionsasshallbenecessaryorappropriatetoeffectuatetheassignmentsandlicensessetforthinthisSection2.3.REPRESENTATIONSANDWARRANTIESBYDDD.DDDmakesthefollowingrepresentationsandwarrantiestoAAA,eachofwhichwillsurvivetheEffectiveDate:3.1TothebestofDDD’sknowledge,thePatentRightsincludeallofthepatentsandpatentapplicationsownedorcontrolledbyDDDonorpriortotheEffectiveDatethatcoverCodeblockerCompoundsandOligonucleotideDeliverySystems,theirmanufactureoruse.TherearenootherUSorunpublishedforeignfilingsownedorcontrolledbyDDDfiledpriortotheEffectiveDatewhichclaimCodeblockerCompoundsorOligonucleotideDeliverySystemsotherthanassetforthinExhibitA,nordoesDDDhaveanypresentintentiontomakesuchfilings.IfDDDbecomesawareofanypatentsorpatentapplicationsthat(i)areownedorcontrolledbyDDD,(ii)claiminventionsmadepriortotheEffectiveDate,(iii)coverCodeblockerCompoundsorOligonucleotideDeliverySystems,and(iv)arenotincludedinExhibitA,DDDwillpromptlynotifyAAAinwritingandexecuteappropriatedocumentstotransfersuchpatentsandpatentapplicationstoAAA.3.2DDDrepresentsandAAAacknowledgesthat(i)theEEEAgreementremainsineffectandDDDandEEEhaveongoingrightsandobligationsthereunder,modifiedtotheextentspecificallysetforthinthisAgreementand(ii)thisAgreementisnotanassignmentofDDD’srightsorobligationsundertheEEEAgreementandthatAAAassumesnorightsorobligationstoEEEunderthisAgreement.DDDrepresentsthattheResearchTermandallrights,obligationsandfundingrelatingtheretoundertheEEEAgreementhavebeenterminated.DDDwillnotenterintoanyfutureamendmentstotheEEEAgreementwhichinanywayaffecttherightsofAAAhereunder.3.3TheEEEAgreementandthelicensetoFFFreferencedinSection2.2abovearetheonlylicensesandDDDisnotawareofanyotherthirdpartyrightsofanykindaffectingthePatentRights.ExceptwithrespecttoU.S.PatentNumber_________,whichissubjecttoaninterferenceproceeding,thePatentRightsarenotthesubjectofanypendinginterference,cancellationorotherprotestproceedingnototherwiseknowntoAAA,orotherwisesubjecttorightsorobligationstoanythirdpartyotherthanEEEandFFF.ThecompletetermsandconditionsofsuchrightsandobligationsrelatingtoEEEandFFFhavebeendisclosedtoAAA.3.4TherearenoCollaborationCompounds(asdefinedinSection1.7oftheEEEAgreement)andnoneweredevelopedduringtheResearchTermundertheEEEAgreement.DDDdoesnotoweanyroyaltiestoEEEoranythirdpartyundertheEEEAgreementnordoesDDDhaveanyknownorpendingclaimsagainstEEEarisingoutoftheEEEAgreement.TothebestofDDD’sknowledge,(i)EEEdoesnotoweanyroyaltiestoDDDoranythirdpartyundertheEEEAgreement,(ii)nordoesEEEhaveanyknownorpendingclaimsagainstDDDarisingoutoftheEEEAgreement.4.TECHNOLOGYTRANSFER.4.1DDDandAAAwillcooperateinthefilingandexecutionofanyandalldocumentsnecessarytoeffectuatetheassignmenttoAAAofthePatentRights,includingthefilingofassignmentsorothertransferoftitlecovenantswiththeU.S.PatentandTrademarkOfficeandforeignpatentofficesasapplicabletothePatentRights.Withinthirty(30)daysfromtheEffectiveDate,DDDwillnotifyallattorneyshandlingtheprosecutionofthePatentRightstocontacttheAAAPatentDepartmenttoprovideanimmediatestatusupdateonthePatentRightsandtopreparethedocumentsnecessarytotransferthePatentRightstoAAA.ThecostofrecordingassignmentsofthePatentRightswillbebornebyAAA.Withinforty-five(45)daysfromtheEffectiveDate,DDDanditscounselwillusetheirreasonablebesteffortstotransferallfilesandsupportingdocumentsrelatingtothePatentRightstoAAA,includingbutnotlimitedto,allinitialinventiondisclosuredocuments,alldocumentssenttotheU.S.PatentandTrademarkOfficeregardinginventionsandclaims,alldraftpatentapplications,allfilingorprosecutiondocumentssubmittedtothepatentoffices,andallfilewrappers.ConceptionnotebooksandallotherdocumentsinthepossessionorunderthecontrolofDDDoritscounselrelatingtoconceptionand/orreductiontopractice,suchasscientistnotebooksshallbeobtainedinaccordwithDDD’sordinarydocumentretentionandmadeavailabletoAAAuponAAA’reasonablerequest.AlldocumentstobeprovidedtoAAAhereunderaretobesentbyexpediteddeliveryservice.4.2DDDwillmakeappropriatescientificstaffavailabletoAAAforascientifictutorialonthesubjectmatterofthisAgreement,suchtutorialnottoexceedmorethan[***]fromDDD’sstaffandnottoobligateDDDtodiscloseanythirdpartyconfidentialinformation.5.PATENTMAINTENANCEANDPROSECUTIONRESPONSIBILITIES.5.1OnandaftertheEffectiveDate,AAAwilltakeresponsibilityforanyactionorproceedinginvolvingPatentRights.ThecostofrecordingtheassignmentofPatentRightsshallbebornesolelybyAAA.IfAAAelectsnottotakesuchresponsibilityinvolvingPatentRight(s)inaparticularcountrythenAAAwilltimelynotifyDDDandEEE30daysbeforethetimefutureactionisdue,andthereafterDDDorEEEshallundertakesuchresponsibility.IfDDDorEEEelectstodoso,AAAwillgrantanynecessaryauthoritytoDDD.DDDwilldeterminewhetherDDDorEEEshalltakesuchresponsibilityattheirexpense.AAAassumesnoobligationtoEEEasaresultofitsagreementwithDDDinthisSectionNOTICEOFINFRINGEMENT.AAAshallpromptlynotifyDDDinwritingofanyinfringementofanyassignedPatentRight(s)ofwhichitbecomesaware.5.3ENFORCEMENTOFPATENTS.ExceptasotherwisesetforthinthisSection,AAAmay,butshallnotberequiredto,prosecuteanyallegedinfringementorthreatenedinfringementofanyassignedPatentRight(s)ofwhichitisawareorwhichisbroughttoitsattention.AAAshallactinitsownnameandatitsownexpense.IfAAAhasfailedtoprosecuteunderthefirstsentenceofthisparagraphwithrespecttoallegedorthreatenedinfringementrelatingtoanyPatentRight(s)(i)twomonthsafterithasbeennotifiedinwritingofsuchallegedinfringement,or(ii)onemonthbeforethetimelimit,ifany,setforthintheappropriatelawsandregulationsforthefilingofsuchactions,whichevercomesfirst,DDD(oratitselectionEEE)may,butshallnotberequiredto,prosecuteanysuchallegedinfringementorthreatenedinfringementofaPatentwithinthePatentRights.Inanysuchevent,DDDorEEEshallbefreetoactinitsownnameandatitsownexpense.Notwithstandingtheforegoingandasbetweentheparties,DDDshallhavethesoleandexclusiverightofenforcementwithrespecttoanyallegedorthreatenedinfringementofanyrightwithinthescopeofthelicensegrantedinSection2.3ofthisAgreement.AAAshallcooperatefullywithDDDorEEEinanyactionbyDDDorEEE,respectively,underthisparagraph,includingifrequiredinordertobringsuchanaction,thefurnishingofapowerofattorney.6.INDEMNITYANDWARRANTY.6.1INDEMNITYBYAAA.AAAwillindemnify,save,defendandholdDDDanditsagents,directorsandemployeesharmlessfromandagainstanyandallsuits,claims,actions,demands,liabilities,expensesand/orloss,includingreasonablelegalexpenseandattorneysfees,resultingfromactivitiesunderthisagreementbyAAA.6.2INDEMNITYBYDDD.DDDwillindemnify,save,defendandholdAAAanditsagents,directorsandemployeesharmlessfromandagainstanyandallsuits,claims,actions,demands,liabilities,expensesand/orloss,includingreasonablelegalexpenseandattorneyfees,resultingfrom(i)DDD’s,DDD’ssublicensee’sorDDD’sassignee’sactivitiesunderthelicensesprovidedforinSections2.3and2.5;(ii)DDD’scontractualobligationstothirdpartiesincludingEEEandFFF,excepttotheextentresultingfromAAA’activitiesunderthisAgreement;or(iii)DDD’sexerciseofthePatentRightspriortotheEffectiveDate.6.3WARRANTY.DDDwarrantsthatithassufficientrightandtitletoenterintoandtoperformitsobligationsunderthisAgreement.EXCEPTASEXPRESSLYSETFORTHINTHISAGREEMENT,THEPARTIESDISCLAIMALLWARRANTIESOFANYNATURE,EXPRESSORIMPLIED,INCLUDINGWITHOUTLIMITATIONWARRANTIESOFVALIDITY,MERCHANTABILITY,NONINFRINGEMENT,ANDFITNESSFORAPARTICULARPURPOSE.7.CONFIDENTIALITY.ConfidentialInformationunderthetermsofthisAgreementisallinformationrelatingtothePatentRightssold,assignedorlicensedtoAAAunderSection2.1andtheTechnologyTransfertoAAAbyDDDunderSection4.1.DDDagreestotreattheConfidentialInformationasconfidentialandtoprotectandmaintaintheconfidentialitythereof.DDDwilluseatleastthesamestandardofcareasitusestoprotectitsownConfidentialInformationtoensurethatitsemployees,agents,andconsultantsdonotdiscloseormakeanyunauthorizeduseofsuchConfidentialInformation.DDDwillpromptlynotifyAAAupondiscoveryofanyunauthorizeduseordisclosureoftheConfidentialInformation.ConfidentialInformationwillnotincludeanyinformationwhichisgenerallyavailabletothepublic,isotherwisepartofthepublicdomainotherthanthroughanyactoromissionofDDDinbreachofthisAgreement,orwhichisrequiredtobedisclosedbylaworcontractenteredintopriortothisAgreement(providedthatAAAshallhavenoticethereofinadvancesothatitcanacttoprotectitsinterestsshoulditdecidetodoso).8.CONSIDERATION.AAAshallpayDDDthefollowingnoncontingent,non-refundablecashpaymentsasconsiderationfortheassignmentsprovidedforinthisAgreement:$,_________ontheEffectiveDate,$,_________onthefirstanniversaryoftheEffectiveDate,$,_________onthesecondanniversaryoftheEffectiveDate,and$,_________onthethirdanniversaryoftheEffectiveDate,fortotalpaymentsof$,_________.IntheeventthatAAAdefaultsonanyofthesepayments,afterthirty(30)daysnoticeandanopportunitytocure,thenownershipofallPatentRightswillautomaticallyreverttoDDDandAAAwilltakeallactionsreasonablyrequestedbyDDDforsuchpurposes,including,withoutlimitation,signinganddeliveringanyapplicableassignmentsandotherdocuments.AAAshallbeentitledtonodamagesexceedingtheconsiderationsetforthinthisSection8foranyuncuredclaimagainstDDDrespectingDDD’sperformanceorrepresentationshereunder.9.NOTICES.NoticesunderthisAgreementshallbesufficientonlyifpersonallydelivered,deliveredbyamajorcommercialrapiddeliverycourierservice,facsimileormailedbycertifiedorregisteredmail,returnreceiptrequested,toapartyatitsaddressessetforthasfollows:IftoAAA:AAA,Inc.Address:_________Attn:_________Facsimile:_________IftoDDD:Address:_________Attn:_________Facsimile:_________IftoEEE:Address:_________Attn:_________Facsimile:_________10.MISCELLANEOUS.IfanyprovisionofthisAgreementshallbeadjudgedbyanycourtofcompetentjurisdictiontobeunenforceableorinvalid,thatprovisionshallbelimitedoreliminatedtotheminimumextentnecessarytocontinuetoeffecttheintentoftheparties,andthisAgreementshallotherwiseremaininfullforceandeffectandenforceable.Anywaiversoramendmentsshallbeeffectiveonlyifmadeinwritingandsignedbyarepresentativeoftherespectivepartiesauthorizedtobindtheparties.ThisAgreementshallbegovernedbythelawsoftheStateofDelaware,excludingconflicts-of-lawprinciples.ThisAgreementisthecompleteandexclusivestatementofthemutualunderstandingofthepartiesandsupersedesandcancelsallpreviouswrittenandoralagreementsandcommunicationsrelatingtothesubjectmatterofthisAgreement,excludingtheConfidentialDisclosureAgreementbetweenthepartiesdated_________,_________,_________(M,D,Y).INWITNESSWHEREOF,thepartieshaveexecutedthisAgreementasofthedayandyearfirstindicated
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- GB/T 1610-2024工業(yè)鉻酸酐
- 【正版授權(quán)】 ISO/TR 11797:2024 EN Ophthalmic optics – Spectacle lenses – Power and prism measurements
- 全面施工合同模板集
- 房屋貸款保險合同參考
- 合作設(shè)立公司合作協(xié)議2024年
- 建筑工程價格調(diào)整合同條款12024年
- 2024年簡易工程委托協(xié)議范本
- 共同生活期間財產(chǎn)分配協(xié)議
- 2024年工廠土地轉(zhuǎn)讓合同書格式
- 環(huán)保搬遷補償安置資金監(jiān)管合同
- 第10課感覺肌理
- 鐵路人工鋪軌技術(shù)交底
- 富士M225打印機無線連接
- B737-300輪艙部件圖
- 各種注射法(課堂PPT)
- 譯林牛津英語7A-unit3-Welcome-to-our-school教案(6課時)
- 第五章 種內(nèi)與種間關(guān)系
- 飛利浦16排螺旋CT機操作規(guī)程(1)
- 油菜品種田間記載項目與標(biāo)準(zhǔn)
- 渣土車輛駕駛員管理制度
- 德力西系列變頻器說明書
評論
0/150
提交評論